Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGILANT depemokimab early add-on therapy in COPD with type 2 inflammation
2025-521108-23-00Phase 3Authorised
- Sponsor
- GSK
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Depemokimab add-on with Placebo add-on (2 arms). Primary endpoint: Annualized rate of moderate/severe exacerbations. Planned start May 2026; status: authorised.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-521108-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521108-23-00.